Session » RA – Treatment Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1399

A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA

10:30AM-12:30PM: Abstract Number: 1385

A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases

10:30AM-12:30PM: Abstract Number: 1379

Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1389

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

10:30AM-12:30PM: Abstract Number: 1376

Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010

10:30AM-12:30PM: Abstract Number: 1388

CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1398

Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort

10:30AM-12:30PM: Abstract Number: 1400

Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer

10:30AM-12:30PM: Abstract Number: 1384

Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 1371

DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1368

Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India

10:30AM-12:30PM: Abstract Number: 1395

Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1375

Effects of Training with Blood Flow Restriction on Muscle Strength in Women with Rheumatoid Arthritis: A Randomized Clinical Trial

10:30AM-12:30PM: Abstract Number: 1381

Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1377

Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1374

Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer

10:30AM-12:30PM: Abstract Number: 1396

Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1367

Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY

10:30AM-12:30PM: Abstract Number: 1366

Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study

10:30AM-12:30PM: Abstract Number: 1394

Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors

10:30AM-12:30PM: Abstract Number: 1387

Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

10:30AM-12:30PM: Abstract Number: 1386

Olokizumab in Real Clinical Practice: Efficacy and Safety

10:30AM-12:30PM: Abstract Number: 1390

One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)

10:30AM-12:30PM: Abstract Number: 1369

Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset

10:30AM-12:30PM: Abstract Number: 1391

Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1383

Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1380

Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib

10:30AM-12:30PM: Abstract Number: 1393

Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials

10:30AM-12:30PM: Abstract Number: 1401

Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1392

Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study

10:30AM-12:30PM: Abstract Number: 1382

Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1397

Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era

10:30AM-12:30PM: Abstract Number: 1373

The Effect of Methotrexate on Lipid and Apolipoprotein Levels in RA Goes Hand-in-hand with EULAR Response

10:30AM-12:30PM: Abstract Number: 1378

Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1372

Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.

10:30AM-12:30PM: Abstract Number: 1370

Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].